First Patient Dosed in Phase II/III COVID-19 Trial
Faron Pharmaceuticals Oy (“Faron” or the “Company”) Faron Pharmaceuticals Doses First Patient in Phase II/III HIBISCUS Trial of Traumakine for Treatment of Hospitalized COVID-19 Patients ·Trial co-funded by US Department of Defense Company announcement, August 25, 2021 at 9.00 AM (EEST)Inside information TURKU, FINLAND / BOSTON, MA – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today